An Open-label, Parallel Group, Phase I Study to Assess the Pharmacokinetics and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Midostaurin (Primary)
- Indications Acute myeloid leukaemia
- Focus Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
- 26 May 2020 Status changed from active, no longer recruiting to completed.
- 03 May 2020 Status changed from recruiting to active, no longer recruiting.
- 22 Apr 2020 Planned End Date changed from 11 Feb 2020 to 5 May 2020.